JP2004534031A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534031A5
JP2004534031A5 JP2002588995A JP2002588995A JP2004534031A5 JP 2004534031 A5 JP2004534031 A5 JP 2004534031A5 JP 2002588995 A JP2002588995 A JP 2002588995A JP 2002588995 A JP2002588995 A JP 2002588995A JP 2004534031 A5 JP2004534031 A5 JP 2004534031A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002588995A
Other languages
Japanese (ja)
Other versions
JP2004534031A (ja
Filing date
Publication date
Priority claimed from IN464MU2001 external-priority patent/IN191028B/en
Application filed filed Critical
Publication of JP2004534031A publication Critical patent/JP2004534031A/ja
Publication of JP2004534031A5 publication Critical patent/JP2004534031A5/ja
Pending legal-status Critical Current

Links

JP2002588995A 2001-05-17 2002-05-10 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 Pending JP2004534031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (https=) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (2)

Publication Number Publication Date
JP2004534031A JP2004534031A (ja) 2004-11-11
JP2004534031A5 true JP2004534031A5 (https=) 2005-09-29

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002588995A Pending JP2004534031A (ja) 2001-05-17 2002-05-10 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物

Country Status (16)

Country Link
US (1) US20030035836A1 (https=)
EP (1) EP1395258A1 (https=)
JP (1) JP2004534031A (https=)
KR (1) KR20040037026A (https=)
CN (1) CN1525855A (https=)
AU (1) AU2002314515B2 (https=)
BE (1) BE1014328A7 (https=)
BR (1) BR0210976A (https=)
CA (1) CA2447005A1 (https=)
HU (1) HUP0400607A3 (https=)
IN (1) IN191028B (https=)
MX (1) MXPA03010501A (https=)
PL (1) PL370589A1 (https=)
RU (1) RU2003133446A (https=)
WO (1) WO2002092078A1 (https=)
ZA (1) ZA200309724B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
ATE381924T1 (de) * 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
KR101468827B1 (ko) 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
JP2005533822A (ja) 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
EP1610768B1 (en) * 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2004093850A1 (en) * 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
ES2655435T3 (es) * 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US8734850B2 (en) 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
UA96457C2 (ru) 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
EP0969818B1 (en) * 1997-03-11 2004-09-08 Arakis Ltd. Dosage forms comprising separate portions of r- and s-enantiomers
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1233768A1 (en) * 1999-11-15 2002-08-28 Smithkline Beecham Carvedilol methanesulfonate
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
JP2003528914A (ja) * 2000-04-03 2003-09-30 エフ.ホフマン−ラ ロシュ アーゲー カルベジロールの濃縮溶液
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Similar Documents

Publication Publication Date Title
BE2019C510I2 (https=)
BE2018C021I2 (https=)
BE2017C049I2 (https=)
BE2017C005I2 (https=)
BE2016C069I2 (https=)
BE2016C040I2 (https=)
BE2016C013I2 (https=)
BE2015C078I2 (https=)
BE2016C002I2 (https=)
BE2018C018I2 (https=)
BE2015C017I2 (https=)
BE2014C053I2 (https=)
BE2014C051I2 (https=)
BE2014C041I2 (https=)
BE2014C030I2 (https=)
BE2014C016I2 (https=)
BE2014C015I2 (https=)
BE2013C063I2 (https=)
BE2013C039I2 (https=)
BE2011C038I2 (https=)
JP2004534031A5 (https=)
BE2015C069I2 (https=)
JP2003180675A5 (https=)
BE2013C046I2 (https=)
JP2003201088A5 (https=)